Hubbry Logo
GuanylyltransferaseGuanylyltransferaseMain
Open search
Guanylyltransferase
Community hub
Guanylyltransferase
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Guanylyltransferase
Guanylyltransferase
Guanylyltransferase
View on Wikipedia
from Wikipedia

Guanylyl transferases are enzymes that transfer a guanosine mono phosphate group, usually from GTP to another molecule, releasing pyrophosphate. Many eukaryotic guanylyl transferases are capping enzymes that catalyze the formation of the 5' cap in the co-transcriptional modification of messenger RNA. Because the 5' end of the RNA molecule ends in a phosphate group, the bond formed between the RNA and the GTP molecule is an unusual 5'-5' triphosphate linkage, instead of the 3'-5' linkages between the other nucleotides that form an RNA strand. In capping enzymes, a highly conserved lysine residue serves as the catalytic residue that forms a covalent enzyme-GMP complex.[1]

The transfer RNA (tRNA) for histidine is unique among eukaryotic tRNAs in requiring the addition of a guanine nucleotide before being aminoacylated by the histidine tRNA synthetase. The yeast guanylyl transferase specific to tRNAHis is unique in being the only known non-tRNA synthetase enzyme that specifically recognizes the tRNA anticodon.[2]

Guanylyl transferases also exist for transferring guanosine nucleotides to sugar molecules, such as mannose and fucose.[citation needed]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Guanylyltransferase

View on Grokipedia
from Grokipedia
Guanylyltransferase is an enzyme that catalyzes the transfer of a guanosine monophosphate (GMP) residue from GTP to the 5'-diphosphate end of nascent pre-mRNA transcripts, forming an unusual 5'-5' triphosphate linkage (GpppN) as the second step in eukaryotic mRNA capping. This cap structure is essential for protecting mRNA from exonucleolytic degradation, facilitating splicing, promoting nuclear export, and enabling efficient translation initiation by ribosomes. In eukaryotes, the enzyme operates co-transcriptionally shortly after transcription initiation by RNA polymerase II, when the nascent RNA is approximately 20 nucleotides long. The catalytic mechanism proceeds in two stages: first, guanylyltransferase forms a covalent lysyl-N-GMP intermediate with GTP, releasing pyrophosphate (PPi); second, the GMP is transferred to the RNA's 5'-diphosphate end (generated by prior RNA triphosphatase activity), requiring a divalent cation such as Mn²⁺ or Mg²⁺ for activity. In mammals, guanylyltransferase comprises the carboxyl-terminal domain (residues 211–597) of the bifunctional mRNA capping enzyme (Mce1), which also includes an amino-terminal RNA triphosphatase domain, forming a 46-kDa monomeric protein with conserved motifs from the covalent nucleotidyl transferase superfamily. The enzyme binds specifically to the phosphorylated carboxyl-terminal domain (CTD) of RNA polymerase II's largest subunit (RPB1), particularly at Ser5 phosphorylation sites, ensuring targeted recruitment to nascent transcripts during the transition from transcription initiation to elongation. Structural studies reveal that the human guanylyltransferase domain adopts an α/β fold with a central seven-stranded β-sheet, featuring key active site residues like Lys-294 (the nucleophile) and Asp-296 within the KXDG motif, which facilitate GMP attachment and transfer. Beyond cellular mRNA capping, guanylyltransferase homologs play critical roles in viral replication; for instance, in coronaviruses like SARS-CoV-2, the NiRAN domain of non-structural protein 12 (nsp12) provides guanylyltransferase activity to cap viral RNA, aiding immune evasion and genome stability, making it a potential antiviral target. In some organisms, such as fungi, guanylyltransferase exists as a separate polypeptide from triphosphatase, while in others like yeast, it is monofunctional (e.g., Ceg1). Related enzymes in the Thg1 family, including tRNAHis guanylyltransferase, catalyze atypical 3'-5' nucleotide additions to tRNA, highlighting the broader evolutionary conservation of guanylylation in RNA modification. Disruption of guanylyltransferase activity impairs mRNA biogenesis and cell viability, underscoring its indispensable role in eukaryotic gene expression.

Discovery and Nomenclature

Historical Background

The discovery of guanylyltransferase activity occurred in the 1970s during investigations into the 5'-terminal modifications of eukaryotic mRNAs, particularly through studies on viral systems that served as models for cellular capping processes. Aaron J. Shatkin and his colleagues at the Roche Institute of Molecular Biology pioneered this work, initially focusing on reovirus mRNAs. In 1975, they identified a methylated, blocked 5'-terminal structure, m⁷GpppGm, in reovirus transcripts, establishing the cap's presence in eukaryotic viral mRNAs and linking it to efficient translation. This breakthrough extended to cellular mRNAs, with Shatkin's group demonstrating similar capped structures in HeLa cell hnRNA, confirming the enzyme's relevance beyond viruses. A key milestone came in 1975 with the initial identification of guanylyltransferase in vaccinia virus systems, where it was purified from virion extracts and shown to catalyze the addition of GMP to the 5'-diphosphate end of mRNA transcripts. Shatkin, along with Mary J. Ensinger and colleagues, isolated soluble guanylyltransferase from vaccinia virus, demonstrating its ability to form a GpppN cap structure on unmethylated viral mRNAs and synthetic homopolymers like poly(A). Concurrently, Bernard Moss's group purified the enzyme from vaccinia virions, revealing its association with a guanine-7-methyltransferase and its role in sequential capping steps, which paralleled observations in phage RNA polymerases but highlighted unique viral adaptations.40646-7/pdf) These findings solidified guanylyltransferase as the enzyme responsible for the guanylylation step in mRNA capping. Early characterizations relied on biochemical assays that exploited radiolabeled GTP to detect enzyme activity. Researchers used [α-³²P]GTP in in vitro reactions with vaccinia extracts or purified enzyme, monitoring the formation of a covalent enzyme-guanylate intermediate (E-pG) via acid-precipitable radioactivity or SDS-PAGE autoradiography, followed by transfer of GMP to diphosphorylated RNA substrates to yield GpppRNA, confirmed by thin-layer chromatography after nuclease digestion. These assays, developed in Shatkin's and Moss's labs, were specific for 5'-diphospho-terminated RNAs and required Mg²⁺, providing the first quantitative measures of guanylyltransferase kinetics and specificity.40646-7/pdf) The nomenclature evolved alongside these discoveries, initially termed "RNA guanylyltransferase" or "mRNA guanylyltransferase" in early papers to reflect its substrate specificity. By the 1980s, it was formally classified under the Enzyme Commission system as EC 2.7.7.50, recognizing its nucleotidyltransferase activity in transferring GMP from GTP to mRNA. This standardization facilitated comparative studies across viral and eukaryotic systems, underscoring the enzyme's conserved mechanism.

Classification and Isoforms

Guanylyltransferases are classified under EC number 2.7.7.50, with the systematic name GTP:mRNA guanylyltransferase, catalyzing the transfer of GMP from GTP to the 5'-diphosphate end of mRNA to form the GpppN cap structure. These enzymes belong to the nucleotidyltransferase superfamily of covalent nucleotidyltransferases, characterized by six conserved motifs (I–VI) that form the active site for nucleotidyl transfer. A key feature is motif I, containing the KxDG sequence where the invariant lysine acts as the nucleophile to form a covalent phosphoamide-linked enzyme-GMP intermediate during catalysis. In eukaryotes, guanylyltransferases exhibit lineage-specific organization and isoforms. In budding yeast (Saccharomyces cerevisiae), the guanylyltransferase activity is provided by the monofunctional Ceg1 protein, encoded by the CEG1 gene, while the associated RNA 5'-triphosphatase is separate (Cet1); these are non-homologous to each other but both essential for capping. In humans, the bifunctional RNGTT protein (also known as HCE or capping enzyme) integrates both triphosphatase and guanylyltransferase activities, encoded by the RNGTT gene located on chromosome 6q15. RNGTT produces multiple isoforms via alternative splicing: the full-length isoform (597 amino acids) is bifunctional, while shorter variants (HCE1A and HCE1B) lack the C-terminal guanylyltransferase domain and retain only triphosphatase activity, with the full-length form predominant in tissues like brain, heart, and liver. Prokaryotes lack dedicated mRNA guanylyltransferases, as mRNA capping is absent in bacterial transcription, but the nucleotidyltransferase superfamily includes prokaryotic ATP-dependent DNA ligases that share the conserved motifs and catalyze analogous nucleotidyl transfer reactions via covalent intermediates. Viral homologs, primarily from DNA viruses infecting eukaryotes, encode guanylyltransferases with varying domain organizations; for example, poxviruses and African swine fever virus produce trifunctional capping enzymes, while Chlorella virus PBCV-1 encodes a monofunctional guanylyltransferase. Structurally, these enzymes feature a conserved mixed α/β fold, with eukaryotic (e.g., human RNGTT guanylyltransferase domain: seven α-helices and 15 β-strands in three antiparallel β-sheets forming an ATP-grasp-like core) and viral homologs (e.g., PBCV-1: similar β-sheet core with flexible lid domains) showing variations in lid conformation and cleft openness that distinguish lineages, such as more rigid β-sheet-dominated active sites in yeast versus dynamic helical lids in viruses.

Molecular Structure

Primary and Secondary Structure

Guanylyltransferases in eukaryotic organisms typically consist of 400–500 amino acids, as exemplified by the Saccharomyces cerevisiae Ceg1 protein, which spans 459 residues and features an N-terminal catalytic domain responsible for guanylylation activity. In mammals, the guanylyltransferase domain forms part of a bifunctional capping enzyme, with the human isoform comprising approximately 339 residues in its minimal active form (residues 229–567 of the full 597-residue protein). Sequence alignments reveal moderate conservation across eukaryotes, with approximately 25–28% amino acid identity between yeast and mammalian guanylyltransferases, primarily concentrated in the catalytic core. This conservation is evident in six signature motifs (I, III, IIIa, IV, V, and VI) that define the active site, including the invariant KxDG element in motif I where the lysine residue forms a covalent phosphoamide linkage with GMP. A notable sequence pattern approximating Gx₅TRx₅Kx₃W spans motifs I and VI, encompassing essential residues for GTP recognition and catalysis that are preserved from fungi to higher eukaryotes. The secondary structure of guanylyltransferases features a mix of alpha-helices and beta-sheets that support nucleotide binding and substrate interaction. In the human enzyme, seven alpha-helices (A–G) flank the nucleotide-binding cleft, while 15 beta-strands organize into three antiparallel sheets, with beta-sheets lining the active site to facilitate GMP transfer. These elements, including helical bundles in the N-terminal lobe for GTP coordination and beta-sheet cores in the C-terminal lobe for catalytic positioning, are broadly conserved across eukaryotic isoforms despite variations in overall sequence. Such secondary structural motifs contribute to the enzyme's tertiary folding into an ATP-grasp configuration essential for activity.

Tertiary Structure and Domains

The tertiary structure of guanylyltransferase (GTase), the enzyme responsible for the guanylylation step in mRNA capping, features a conserved bilobal architecture comprising a nucleotidyltransferase core domain and a C-terminal regulatory domain. The core domain adopts an ATP-grasp fold characteristic of nucleotidyltransferases and DNA ligases, consisting of two subdomains—a base subdomain and a hinge subdomain—that form a cleft for substrate binding. Overlying this core is an oligonucleotide/oligosaccharide-binding (OB)-fold domain that functions as a swivel lid, regulating access to the active site through conformational changes between open and closed states. Crystal structures of eukaryotic GTases, such as the human mRNA guanylyltransferase (hGTase) domain (residues 229–567), reveal this fold in detail. Solved at 3.0 Å resolution (PDB ID: 3S24), the hGTase structure shows seven α-helices and 15 β-strands organized into three antiparallel β-sheets, with the GTP-binding pocket located between the base (residues 271–415) and hinge (residues 229–270, 416–461, and 553–567) subdomains. The OB-fold lid (residues 462–552) exhibits positional variability across seven conformers in the asymmetric unit, demonstrating a swivel motion that modulates the active site cleft from closed to half-open states, facilitating GTP binding and GMP transfer. Key active site residues include Lys-294, which forms a covalent phosphoamide linkage with GMP, and Asp-297 within the conserved KXDG motif, alongside an electropositive track lined by motifs V and VI for phosphate/RNA interactions. In contrast to the monomeric structure of eukaryotic GTases like hGTase, which lacks disulfide bonds despite eight cysteines, viral forms often involve dimerization interfaces for functional assembly. For instance, the vaccinia virus capping enzyme is a heterodimer of the D1 subunit (containing GTase activity, residues 1–545) and the regulatory D12 subunit, where the dimer interface stabilizes the complex and enhances catalytic efficiency, as evidenced by biochemical and crystallographic studies (PDB ID: 4CKB). Evolutionary structural divergence among GTases is apparent in domain insertions and surface variations, particularly in phage-derived enzymes. The Paramecium bursaria chlorella virus 1 (PBCV-1) GTase, a phage homolog, retains the core ATP-grasp and OB-fold but features distinct insertions in the lid domain, resulting in rmsd values of ~3 Å when superimposed on hGTase (PDB IDs: 1CKM, 1CKN). These insertions contribute to phage-specific adaptations, such as cytoplasmic function independent of host polymerases, while conserving the GTP pocket and cleft electropositivity across eukaryotes, viruses, and phages. Yeast GTases (e.g., Saccharomyces cerevisiae, PDB ID: 3KYH) show wider cleft openings and greater rmsd (~5 Å), highlighting progressive divergence from viral/phage ancestors to metazoan forms optimized for nuclear transcription machinery interactions.

Catalytic Mechanism

Reaction Overview

Guanylyltransferase catalyzes the transfer of a guanosine monophosphate (GMP) moiety from guanosine triphosphate (GTP) to the 5'-diphosphate terminus of nascent pre-mRNA, forming an unmethylated cap structure G(5')ppp(5')N-RNA and releasing inorganic pyrophosphate (PPi). The overall reaction can be summarized as: enzyme + GTP + ppRNA → enzyme + PPi + GpppRNA, where ppRNA represents the RNA substrate with a 5'-diphosphorylated end generated by prior action of an RNA triphosphatase. This step is the second in the mRNA capping pathway and establishes the inverted cap orientation essential for subsequent methylation. The catalytic mechanism follows a two-step ping-pong bi-bi pathway. In the first step, GTP binds to the enzyme's active site, where a conserved lysine residue attacks the α-phosphate of GTP, displacing PPi and forming a covalent phosphoamide-linked enzyme-GMP intermediate. In the second step, this intermediate binds the 5'-diphosphate end of the RNA acceptor, transferring the GMP to form the GpppN linkage and regenerating the free enzyme. This ordered mechanism ensures efficient substrate utilization and is conserved across eukaryotic and viral guanylyltransferases. Guanylyltransferases exhibit strong substrate specificity for GTP as the guanylyl donor, with minimal activity toward other nucleoside triphosphates such as ATP, UTP, or CTP. Kinetic studies indicate Km values for GTP in the range of 10–50 μM, reflecting high affinity suited to intracellular GTP concentrations. The enzyme also prefers 5'-diphosphorylated RNA acceptors over triphosphorylated ends, although the latter can serve in some contexts. The reaction's thermodynamics favor forward progression in cellular environments due to the hydrolysis of released PPi by ubiquitous pyrophosphatases, which shifts the equilibrium by removing the product and rendering the overall process effectively irreversible. Although the isolated guanylylation is reversible in vitro (with equilibrium constants near unity), cellular PPi concentrations remain low (~0.1–1 μM), driving net cap formation with a free energy change estimated at ΔG°' ≈ -7 to -10 kcal/mol when coupled to PPi hydrolysis.

Key Residues and Intermediates

In guanylyltransferases, the catalytic mechanism involves a conserved active site where a lysine residue (e.g., Lys-196 in human Mce1 or Lys-70 in yeast Ceg1) acts as the nucleophile, attacking the α-phosphate of GTP to form a covalent phosphoamide intermediate with GMP; this is part of the conserved KXDG motif. Mutational analysis in homologous yeast Ceg1 enzyme, where the equivalent lysine is changed to alanine (K to A), completely abolishes guanylylation activity, confirming its essential role as the nucleophile. Conserved aspartate residues (e.g., Asp-198 in human) contribute to metal ion coordination in the active site, facilitating the binding of divalent cations such as Mg²⁺ or Mn²⁺ that stabilize the transition state during phosphate transfer. These residues, along with others, help position the triphosphate chain and promote deprotonation of the lysine for enhanced nucleophilicity. The enzyme undergoes a conformational change to a closed state upon GTP binding, positioning the lysine for attack. The catalytic cycle features a key covalent intermediate, enzyme-Lys-GMP, formed in the first step, where GTP reacts to yield the phosphoamide-linked GMP and release pyrophosphate (PPᵢ). This intermediate then transfers GMP to the 5'-diphosphate RNA acceptor. The first step can be represented as: E+GTP⇌E-Lys-GMP+PPi\text{E} + \text{GTP} \rightleftharpoons \text{E-Lys-GMP} + \text{PP}_\text{i} This equilibrium favors intermediate formation under physiological conditions, driven by the exergonic release of PPᵢ. Structural studies of the guanylylated intermediate reveal the lysine Nζ bonded directly to the GMP α-phosphate, stabilized by hydrogen bonding networks involving nearby aspartates.

Biological Roles

Role in mRNA Capping

Guanylyltransferase catalyzes the transfer of GMP from GTP to the 5'-diphosphate end of nascent pre-mRNA, forming a GpppN linkage that serves as the precursor to the mature m7G cap structure essential for mRNA stability, nuclear export, splicing, and translation initiation. This reaction occurs co-transcriptionally during early elongation, typically when the RNA transcript is 20-60 nucleotides long, just downstream of the promoter, allowing capping before productive elongation proceeds. The timing is facilitated by recruitment to the phosphorylated C-terminal domain (CTD) of RNA polymerase II, particularly Ser5 phosphorylation, which allosterically activates the enzyme and coordinates with promoter-proximal pausing mediated by DSIF and NELF factors. In eukaryotic cells, guanylyltransferase integrates into a multi-enzyme capping complex alongside RNA 5'-triphosphatase (RT), which first removes the γ-phosphate from the primary transcript's 5'-triphosphate end, and RNA (guanine-N7) methyltransferase (RNMT), which methylates the added guanosine to yield the functional m7GpppN cap. In budding yeast (Saccharomyces cerevisiae), guanylyltransferase (Ceg1) and RT (Cet1) form a stable heterotetrameric complex (Cet12Ceg12) that binds the Ser5-phosphorylated Pol II CTD and additional Pol II subunits like Rpb1 and Rpb7 for precise targeting. In mammals, including humans, guanylyltransferase and RT activities reside in the bifunctional capping enzyme RNGTT, which forms a ternary complex with RNMT and associates with elongating Pol II via CTD interactions, ensuring efficient sequential action during transcription initiation. This complex architecture enhances capping fidelity and prevents uncapped transcripts from accumulating, which would otherwise lead to mRNA degradation. Guanylyltransferase is indispensable for eukaryotic viability, reflecting its central role in mRNA maturation and gene expression. In yeast, deletion of the CEG1 gene is lethal, with null mutants inviable due to defective mRNA capping, accumulation of uncapped pre-mRNAs, and impaired transcription elongation and promoter escape. Human RNGTT likewise appears essential, as its depletion disrupts mRNA stability and processing, and perturbations in the capping pathway, including RNGTT-related components, are associated with developmental disorders such as congenital dyserythropoietic anemia. These findings underscore the evolutionary conservation of guanylyltransferase's function in sustaining cellular homeostasis through proper mRNA cap formation.

Involvement in Viral Replication

Guanylyltransferases play a critical role in viral replication by enabling the capping of viral mRNAs, which facilitates translation and helps viruses evade host innate immune responses. In poxviruses such as vaccinia virus, the virus encodes a multifunctional capping enzyme complex that includes a guanylyltransferase subunit (D1R), which transfers GMP from GTP to the 5'-diphosphate end of nascent viral transcripts to form the cap structure. This viral capping activity is essential for efficient viral mRNA translation in the cytoplasm and contributes to immune evasion by mimicking host capped mRNAs, thereby avoiding detection by pattern recognition receptors like RIG-I. Similarly, in orbiviruses like bluetongue virus, the VP4 protein functions as a guanylyltransferase that caps viral mRNAs, supporting replication in infected cells. In bacteriophage T7 systems, guanylyltransferase is integrated into in vitro transcription workflows alongside T7 RNA polymerase to produce capped synthetic RNAs. T7 RNA polymerase transcribes DNA templates into uncapped RNAs, after which guanylyltransferase—often derived from vaccinia virus—is added to catalyze cap formation, enhancing mRNA stability and translational efficiency in research and therapeutic applications like mRNA vaccines. This co-utilization highlights the enzyme's utility in mimicking eukaryotic capping for viral-like RNA production outside natural infection contexts. Certain viruses exploit host guanylyltransferases through antagonism mechanisms, such as cap snatching in influenza A virus, where the viral polymerase hijacks capped host transcripts generated by cellular RNGTT (RNA guanylyltransferase and 5'-phosphatase) to prime viral mRNA synthesis. This process allows influenza to bypass de novo capping, directly utilizing host-modified caps to ensure viral genome expression while depleting host translation resources. Viral guanylyltransferases have served as key models for understanding the evolution of eukaryotic mRNA capping machinery, with structures from viruses like vaccinia revealing conserved mechanisms that informed studies on host enzymes. Comparative analyses suggest that these viral enzymes, often simpler in form, reflect ancient prokaryotic or early eukaryotic origins, providing insights into how capping evolved to support RNA processing across domains.

Regulation and Inhibitors

Cellular Regulation

Guanylyltransferase activity is tightly regulated at the post-translational level to ensure precise mRNA capping during transcription. In mammals, the guanylyltransferase domain of RNGTT binds directly to the Ser5-phosphorylated C-terminal domain (CTD) of RNA polymerase II, which recruits the enzyme to the nascent pre-mRNA and allosterically stimulates its catalytic activity up to 2.2-fold by stabilizing the active site conformation through disruption of inhibitory salt bridges (e.g., involving residues R358, R411, and E436). This interaction is specific to Ser5 phosphorylation; binding to Ser2-phosphorylated CTD occurs but does not activate the enzyme, highlighting phosphorylation-dependent control of capping efficiency during early transcription elongation. In yeast, the guanylyltransferase Ceg1 exhibits autoinhibitory regulation via direct binding to the phosphorylated CTD of RNA polymerase II, which suppresses formation of the enzyme-GMP intermediate and prevents premature capping. This inhibition is relieved by interaction with the triphosphatase subunit Cet1, whose C-terminal domain (residues 205–265) binds Ceg1 and restores guanylyltransferase activity approximately 2-fold while also stabilizing the enzyme complex against thermal denaturation and degradation. Such allosteric modulation coordinates the sequential steps of capping and links enzyme function to the transcription cycle. Transcriptional control of guanylyltransferase expression supports cellular demands during proliferation, though specific mechanisms remain underexplored. RNGTT protein levels are altered in proliferating cells, with depletion impairing proliferation specifically in c-Myc-overexpressing mammalian cells, indicating indirect regulation tied to oncogenic pathways like c-Myc, which recruits but does not directly transcribe RNGTT. In yeast, CET1 expression is constitutive and essential for viability, with no identified feedback from capped mRNA levels reported.

Known Inhibitors and Therapeutics

Guanylyltransferases, essential for mRNA capping in both cellular and viral contexts, have been targeted by small-molecule inhibitors that disrupt GTP binding or enzyme conformational dynamics. GTP analogs, such as 7-methylguanosine triphosphate (m⁷GTP) and related cap structures like m²,⁷GpppG, act as competitive inhibitors by mimicking the natural substrate and competing for the GTP-binding pocket in viral guanylyltransferases, such as those in alphaviruses. For instance, in Semliki Forest virus nsP1, analogs like et₂m⁷GMP exhibit mixed-type inhibition with Ki values around 42 μM, blocking both guanylylation and subsequent methyl transfer steps essential for cap formation. These compounds prevent the formation of the covalent enzyme-GMP intermediate, thereby inhibiting viral mRNA maturation with potencies in the low micromolar range. Allosteric inhibitors, including mizoribine monophosphate (MZP), target sites outside the active center to modulate enzyme activity. MZP, the active metabolite of the approved immunosuppressant mizoribine, non-competitively inhibits human RNA guanylyltransferase with an IC₅₀ of 80 μM for the full reaction, primarily by hindering conformational changes required for GMP transfer to RNA, while showing minimal effect on the initial GTP hydrolysis step (IC₅₀ ≈ 3 mM). This allosteric mechanism, potentially involving interdomain regions near the C-terminal, suggests opportunities for peptides mimicking the RNA 5' diphosphate end to sterically block substrate access, though specific peptide inhibitors remain exploratory. In viral systems, such as flaviviruses, thioxothiazolidinone derivatives like BG-323 competitively bind the GTP pocket (Ki ≈ 7.5 μM) via hydrogen bonding and hydrophobic interactions, disrupting guanylylated enzyme intermediate formation. Therapeutically, guanylyltransferase inhibitors hold promise for antiviral development by impairing viral mRNA capping and stability. Remdesivir triphosphate, an approved nucleotide analog for SARS-CoV-2 treatment, inhibits the viral guanylyltransferase (nsp12 NiRAN domain) with potency comparable to its RNA polymerase inhibition, reducing cap formation and viral replication. Similar approaches target poxvirus guanylyltransferases, where GTP-competitive inhibitors could disrupt orthopoxvirus mRNA processing, complementing existing antivirals like tecovirimat. For flaviviruses, BG-323 analogs show EC₅₀ values around 30 μM in cell-based assays against dengue and West Nile viruses, highlighting broad-spectrum potential against RNA viruses lacking approved therapies. In cancer contexts, inhibiting cellular guanylyltransferases could destabilize oncogenic mRNAs by uncapping, reducing translation efficiency and promoting decay, though this remains preclinical with links to mRNA stability pathways. Clinical development focuses on early-stage optimization of GTP analogs and allosteric modulators for RNA virus infections, with remdesivir demonstrating translatable efficacy.

Research Applications

Biochemical Assays

Biochemical assays for guanylyltransferase activity primarily measure the enzyme's ability to transfer the guanylyl moiety (GMP) from GTP to the 5'-diphosphate end of RNA (ppRNA), forming an inverted GpppN cap structure. These assays are essential for characterizing enzyme kinetics, identifying active domains, and screening potential inhibitors, with methods evolving from radioactive labeling to non-radioactive techniques for safety and scalability. The standard in vitro assay employs radiolabeled [α-³²P]GTP as the donor substrate and synthetic ppRNA (typically 20–80 nucleotides long, generated by treating triphosphate RNA with RNA triphosphatase) as the acceptor. The reaction proceeds in two steps: first, formation of a covalent enzyme-[³²P]GMP intermediate (Lys-N-GMP), followed by transfer to ppRNA yielding G[³²P]pppRNA. For the transfer step, reaction mixtures (typically 20–50 μl containing 50 mM Tris-HCl pH 8.0, 5 mM DTT, 5 mM MgCl₂, 0.1–10 μM [α-³²P]GTP, 10–50 pmol ppRNA, and 10–100 ng enzyme) are incubated at 37°C for 5–30 min, quenched with EDTA, and products separated by thin-layer chromatography (TLC) on polyethyleneimine (PEI)-cellulose plates developed in 0.4–0.75 M potassium phosphate (pH 3.4–4.3). Capped RNA (GpppN) migrates ahead of GTP and pyrophosphate (PPᵢ), allowing quantification via phosphorimaging or scintillation counting; yields are often 20–80% under optimal conditions. This method, adapted from early studies on vaccinia virus enzyme, is routinely used for eukaryotic guanylyltransferases including human RNGTT due to its sensitivity for low enzyme amounts. To detect the enzyme-GMP intermediate specifically, assays utilize SDS-polyacrylamide gel electrophoresis (PAGE). Purified enzyme (e.g., recombinant human RNGTT residues 229–567) is incubated with [α-³²P]GTP under similar conditions, quenched with SDS sample buffer, and resolved on 10–12% gels; the labeled ~40–50 kDa band is visualized by autoradiography. This step quantifies initial velocity without RNA, revealing Km values for GTP of ~0.1–0.5 μM and dependence on divalent cations (Mg²⁺ or Mn²⁺ optimal at 1–10 mM). For human RNGTT, full-length enzyme shows ~30% labeling efficiency at saturating GTP, with the minimal GTase domain (residues 229–567) retaining near-wild-type activity. Non-radioactive alternatives, such as HPLC-based methods, enable quantification of GMP transfer without isotopes, suitable for structural and inhibitor studies. In these assays, reactions use unlabeled GTP and fluorescently or biotin-labeled ppRNA; products are digested (e.g., with nuclease P1) and separated by reverse-phase HPLC (C18 column, gradient of ammonium acetate/acetonitrile), with capped species detected by UV absorbance at 260 nm or mass spectrometry (m/z shift for GpppN vs. ppN). Conversion efficiencies reach 70–90% for optimized systems, allowing kinetic analysis via initial rates. These methods avoid waste disposal issues and support scale-up. Kinetic parameters for human RNGTT guanylyltransferase activity include Vmax values around 20 nmol/min/mg for GMP transfer under saturating conditions (5 mM Mg²⁺, pH 8.0), derived from mouse ortholog studies extrapolated to human due to high sequence conservation (>90% identity in GTase domain). Km for GTP is ~0.2 μM, and for ppRNA ~1–5 μM, with Mn²⁺ supporting higher rates than Mg²⁺. Inhibition studies often use these assays to measure IC50 for compounds targeting the active site lysine; for example, analogs like GTPγS competitively inhibit with IC50 ~10–50 μM, blocking intermediate formation. High-throughput screening adaptations modify the transfer assay for inhibitor discovery, particularly against viral homologs but applicable to human RNGTT. Fluorescence polarization (FP) uses BODIPY-labeled GTP analogs (e.g., BODIPY-GTPγS, Kd ~100 nM); enzyme binding increases polarization, and inhibitors reduce it in 384- or 1536-well formats, enabling screening of >10,000 compounds with Z' factors >0.7. ELISA-based variants capture enzyme-GMP on plates and detect via anti-GMP antibodies, quantifying colorimetrically for IC50 determination (e.g., <10 μM hits). These facilitate drug development targeting capping for antiviral or anticancer therapies.

Structural Studies

The first high-resolution structure of a guanylyltransferase was determined using X-ray crystallography on the enzyme from Paramecium bursaria chlorella virus 1 (PBCV-1), revealing two distinct conformational states—an open form and a closed form—at 2.5 Å resolution (PDB: 1CKM). This milestone structure, published in 1997, demonstrated a bilobed architecture with a deep cleft between the N-terminal guanylyltransferase domain and the C-terminal domain, highlighting the enzyme's ability to undergo large-scale rearrangements during the guanylyl transfer reaction. Subsequent X-ray studies, such as the 2011 structure of the human mRNA guanylyltransferase domain at 2.3 Å resolution (PDB: 3S24), confirmed evolutionary conservation of the GTP-binding site while revealing multiple conformational states that inform the catalytic mechanism. Cryo-electron microscopy (cryo-EM) has enabled visualization of guanylyltransferase in larger cellular complexes, particularly its association with RNA polymerase II (Pol II) during co-transcriptional mRNA capping. A 2023 cryo-EM study resolved the structure of the human capping machinery, including RNA guanylyltransferase and 5'-phosphatase (RNGTT), bound to transcribing Pol II at an overall resolution of 3.6 Å, with the Pol II core at 3.1 Å. This work illuminated the spatial organization of the capping apparatus on paused Pol II, showing how guanylyltransferase positions near the nascent RNA exit channel to facilitate substrate access. More recent cryo-EM analyses, such as a 2024 structure of the Pol II elongation complex with RNGTT at 3.5 Å resolution, further detailed interactions that stabilize the enzyme on promoter-proximal DNA. Computational modeling, including molecular docking simulations, has predicted binding modes of potential inhibitors to guanylyltransferase active sites. A 2011 virtual high-throughput screening study used docking to identify mycophenolic acid as an inhibitor that occupies the GTP-binding pocket, preventing GMP transfer with an IC50 of approximately 10 μM. Such simulations, often based on PDB structures like 1CKM, guide rational drug design by forecasting how small molecules disrupt key residues in the catalytic cleft, aiding development of antiviral therapeutics targeting viral guanylyltransferases.

References

  1. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/guanylyl-transferase
  2. https://www.jbc.org/article/S0021-9258(18)46171-6/fulltext
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3121809/
  4. https://www.nature.com/articles/s41586-022-05185-z
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2996709/
  6. https://enzyme.expasy.org/EC/2.7.7.50
  7. https://www.uniprot.org/uniprotkb/O60942/entry
  8. https://www.pnas.org/doi/10.1073/pnas.94.18.9573
  9. https://www.omim.org/entry/603512
  10. https://www.pnas.org/doi/10.1073/pnas.1106610108
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4010090/
  12. https://www.pnas.org/doi/10.1073/pnas.78.1.187
  13. https://www.jbc.org/article/S0021-9258(18)53231-4/fulltext
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC1134125/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC19065/
  16. https://www.yeastgenome.org/locus/S000003098
  17. https://www.genecards.org/cgi-bin/carddisp.pl?gene=RNGTT
  18. https://pubmed.ncbi.nlm.nih.gov/6264433/
  19. https://www.nature.com/articles/nrmicro2675
  20. https://viralzone.expasy.org/preview_by_protein/11265
  21. https://www.thermofisher.com/us/en/home/references/ambion-tech-support/probe-labeling-systems/general-articles/the-basics-in-vitro-transcription.html
  22. https://www.cytivalifesciences.com/en/us/insights/in-vitro-transcription-for-mrna-synthesis
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8008163/
  24. https://www.biorxiv.org/content/10.1101/2024.08.11.607481v1.full-text
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC317247/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7131690/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8034621/
  28. https://genesdev.cshlp.org/content/12/22/3482.full
  29. https://www.nature.com/articles/s41598-024-78152-5
  30. https://www.sciencedirect.com/science/article/abs/pii/S016635429900011X
  31. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0054621
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC3421717/
  33. https://www.biorxiv.org/content/10.1101/2021.03.17.435913v1
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC9758798/
  35. https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202100291
  36. https://www.cell.com/molecular-cell/fulltext/S1097-2765(23)00424-0
  37. https://www.nature.com/articles/s41467-024-48963-1
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3174198/
Add your contribution
Related Hubs
User Avatar
No comments yet.